BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21290246)

  • 1. A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
    Choi YH; Kim TW; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Kang YK
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):905-12. PubMed ID: 21290246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
    Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
    Tsunoda A; Yasuda N; Nakao K; Narita K; Yamazaki K; Watanabe M; Suzuki N; Kusano M
    Oncology; 2007; 72(1-2):58-63. PubMed ID: 17998791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
    Takiuchi H; Narahara H; Tsujinaka T; Gotoh M; Kawabe S; Katsu K; Iishi H; Tatsuta M; Fujitani K; Furukawa H; Taguchi T;
    Jpn J Clin Oncol; 2005 Sep; 35(9):520-5. PubMed ID: 16141295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
    Takii Y; Yamazaki T; Okada T; Tani T; Funakoshi K; Maruyama S; Hasegawa J; Akazawa K; Hatakeyama K;
    Chemotherapy; 2013; 59(5):338-43. PubMed ID: 24820531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of CPT-11 and S-1 combination chemotherapy in patients with metastatic colorectal cancer.
    Yamaguchi Y; Minami K; Kawabuchi Y; Ohshita A; Hironaka K
    Hepatogastroenterology; 2008; 55(82-83):407-11. PubMed ID: 18613376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
    Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
    Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
    Inokuchi M; Yamashita T; Yamada H; Kojima K; Ichikawa W; Nihei Z; Kawano T; Sugihara K
    Br J Cancer; 2006 Apr; 94(8):1130-5. PubMed ID: 16570038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
    Tsunoda A; Yasuda N; Nakao K; Narita K; Watanabe M; Matsui N; Kusano M
    Oncology; 2009; 77(3-4):192-6. PubMed ID: 19729976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
    Doi T; Yoshino T; Fuse N; Boku N; Yamazaki K; Koizumi W; Shimada K; Takinishi Y; Ohtsu A
    Invest New Drugs; 2015 Oct; 33(5):1068-77. PubMed ID: 26163340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
    Yoda S; Soejima K; Yasuda H; Naoki K; Kawada I; Watanabe H; Nakachi I; Satomi R; Nakayama S; Ikemura S; Terai H; Sato T; Morosawa M; Asano K
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):717-22. PubMed ID: 21152917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Kishimoto J; Uchino K; Arita S; Kumagai H; Mitsugi K; Akashi K; Baba E
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):29-34. PubMed ID: 23228984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
    Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
    Okabayashi K; Hasegawa H; Ishii Y; Endo T; Ochiai H; Kubota T; Kitagawa Y
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):501-7. PubMed ID: 18461329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
    Ogata Y; Sasatomi T; Akagi Y; Ishibashi N; Mori S; Shirouzu K
    Kurume Med J; 2009; 56(1-2):1-7. PubMed ID: 20103995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
    Sasaki Y; Hamaguchi T; Arai T; Goto A; Ura T; Muro K; Yamada Y; Shirao K; Shimada Y
    Anticancer Res; 2014 Apr; 34(4):2029-34. PubMed ID: 24692743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.
    Shiozawa M; Sugano N; Tsuchida K; Morinaga S; Akaike M; Sugimasa Y
    J Cancer Res Clin Oncol; 2009 Mar; 135(3):365-70. PubMed ID: 18974999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.